Latest / Breastcancer.org Podcast
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines.
Listen to the episode to hear Dr. Bardia explain:
results of the study
what HER2-low and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.